ClinicalTrials.gg
CompletedNCT06360419PARADIGMUpdated Jan 5, 2026

Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol

A Phase 3 interventional study of Solriamfetol 300 mg and Placebo in Major Depressive Disorder, sponsored by Axsome Therapeutics, Inc.. Completed at 40 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Axsome Therapeutics, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 10 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Dec 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
346
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc. — 2 open to participants now, 2 under way, 1 of them phase 3. Depressive Disorder, Major · Axsome Therapeutics, Inc..

Enrollment
4th of 10
346 · median 320
Started
2024
the only one that year
Phase 3
5 of 10
1 open now
Registered
9th of 10
by date

Among the 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc., this one is the 4th largest by enrollment, is the only one that started in 2024, is one of 5 in phase 3, and was the 9th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

2 of the 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc., or all of them as a file.
02

Study summary

PARADIGM (Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the safety and efficacy of solriamfetol for the treatment of major depressive disorder (MDD) in adults.

Read the detailed description

Eligible subjects must have a primary diagnosis of MDD without psychotic features based on the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria. Subjects will be randomized in a 1:1 ratio to receive either solriamfetol (300 mg) or placebo for 6 weeks.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Solriamfetol
  • Sunosi
  • MDD
  • Major Depressive Disorder
  • Axsome
  • Non-stimulant therapy
  • Dopamine norepinephrine reuptake inhibitor
  • Trace amine-associated receptor 1 (TAAR1) agonist
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently meets the criteria for MDD without psychotic features, based on the SCID-5-CT
  • Current major depressive episode
  • Male or female, aged 18 to 65 inclusive

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to solriamfetol/Sunosi, through either a clinical study or prescription
  • Unable to comply with study procedures
  • Medically inappropriate for study participation in the opinion of the investigator
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
346 participants (actual)

Study arms

  • Experimental
    Solriamfetol 300 mg

    Up to 6 weeks

    Drug: Solriamfetol 300 mg

  • Placebo comparator
    Placebo

    Up to 6 weeks

    Drug: Placebo

Interventions

  • Solriamfetol tablets, taken once daily

  • DrugPlacebo

    Placebo tablets, taken once daily

06

What researchers measure

Primary outcomes

  1. Montgomery-Åsberg Depression Rating Scale (MADRS)

    Time frame: 6 weeks

  2. Incidence of treatment-emergent adverse events

    Time frame: 6 weeks

07

Study locations

40 sites
  • Clinical Research Site
    Little Rock, Arkansas 72211, United States
  • Clinical Research Site
    Bellflower, California 90706, United States
  • Clinical Research Site
    Encino, California 91316, United States
  • Clinical Research Site
    Lemon Grove, California 91945, United States
  • Clinical Research Site
    Los Angeles, California 90015, United States
  • Clinical Research Site
    Montclair, California 91763, United States
  • Clinical Research Site
    Oceanside, California 92056, United States
  • Clinical Research Site
    Redlands, California 92374, United States
  • Clinical Research Site
    Riverside, California 92506, United States
  • Clinical Research Site
    Sherman Oaks, California 91403, United States
  • Clinical Research Site
    Torrance, California 90501, United States
  • Clinical Research Site
    Upland, California 91786, United States
  • Clinical Research Site
    Walnut Creek, California 94596, United States
  • Clinical Research Site
    Cromwell, Connecticut 06416, United States
  • Clinical Research Site
    Brandon, Florida 33511, United States
  • Clinical Research Site
    Hialeah, Florida 33012, United States
  • Clinical Research Site
    Jacksonville, Florida 32256, United States
  • Clinical Research Site
    Orlando, Florida 32801, United States
  • Clinical Research Site
    Orlando, Florida 32806, United States
  • Clinical Research Site
    Orlando, Florida 32807, United States
  • Clinical Research Site
    Chicago, Illinois 60634, United States
  • Clinical Research Site
    Overland Park, Kansas 66210, United States
  • Clinical Research Site
    New Orleans, Louisiana 70115, United States
  • Clinical Research Site
    Boston, Massachusetts 02131, United States
  • Clinical Research Site
    Saint Charles, Missouri 63304, United States
  • Clinical Research Site
    Las Vegas, Nevada 89102, United States
  • Clinical Research Site
    Brooklyn, New York 11235, United States
  • Clinical Research Site
    Rochester, New York 14609, United States
  • Clinical Research Site
    Staten Island, New York 10314, United States
  • Clinical Research Site
    Hickory, North Carolina 28601, United States
  • Clinical Research Site
    Cincinnati, Ohio 45215, United States
  • Clinical Research Site
    Oklahoma City, Oklahoma 73116, United States
  • Clinical Research Site
    Media, Pennsylvania 19063, United States
  • Clinical Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Clinical Research Site
    Memphis, Tennessee 38119, United States
  • Clinical Research Site
    Austin, Texas 78737, United States
  • Clinical Research Site
    Dallas, Texas 75231, United States
  • Clinical Research Site
    Friendswood, Texas 77546, United States
  • Clinical Research Site
    Wichita Falls, Texas 76309, United States
  • Clinical Research Site
    Everett, Washington 98201, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Dec 2024, 9 months.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 9 months is below that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2024
First posted
Apr 11, 2024
StartActual
Mar 18, 2024
Primary completionActual
Dec 31, 2024
CompletionActual
Mar 26, 2025
Results delay requested
Dec 30, 2025
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06360419
Responsible party
Sponsor
First posted
Apr 11, 2024
Start date
Mar 18, 2024
Primary completion
Dec 31, 2024
Completion
Mar 26, 2025
Last update
Jan 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solriamfetol

Start the discussion